Literature DB >> 36248205

Identification of cutaneous immune-related adverse events by International Classification of Diseases codes and medication administration.

Wenxin Chen1,2, Guihong Wan1, Nga Nguyen1, Bonnie Leung1, Jun Wen2, Michael R Collier1, Shawn G Kwatra3, Yevgeniy R Semenov1.   

Abstract

Entities:  

Year:  2022        PMID： 36248205      PMCID： PMC9563326          DOI： 10.1016/j.jdin.2022.08.001

Source DB:  PubMed          Journal:  JAAD Int        ISSN： 2666-3287


× No keyword cloud information.
  4 in total

1.  Calculating the benefits of a Research Patient Data Repository.

Authors:  Ruth Nalichowski; Diane Keogh; Henry C Chueh; Shawn N Murphy
Journal:  AMIA Annu Symp Proc       Date:  2006

2.  Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.

Authors:  Kimberly Tang; Jayhyun Seo; Bruce C Tiu; Thomas K Le; Vartan Pahalyants; Neel S Raval; Pearl O Ugwu-Dike; Leyre Zubiri; Vivek Naranbhai; Mary Carrington; Alexander Gusev; Kerry L Reynolds; Nicole R LeBoeuf; Maryam M Asgari; Shawn G Kwatra; Yevgeniy R Semenov
Journal:  JAMA Dermatol       Date:  2022-02-01       Impact factor: 10.282

3.  Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.

Authors:  Shannon Wongvibulsin; Vartan Pahalyants; Mark Kalinich; William Murphy; Kun-Hsing Yu; Feicheng Wang; Steven T Chen; Kerry Reynolds; Shawn G Kwatra; Yevgeniy R Semenov
Journal:  J Am Acad Dermatol       Date:  2021-04-02       Impact factor: 11.527

4.  Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.

Authors:  Mark Kalinich; William Murphy; Shannon Wongvibulsin; Vartan Pahalyants; Kun-Hsing Yu; Chenyue Lu; Feicheng Wang; Leyre Zubiri; Vivek Naranbhai; Alexander Gusev; Shawn G Kwatra; Kerry L Reynolds; Yevgeniy R Semenov
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.